“Clinical Reasons” Cited As Factor Behind ASR Hip Recall

According to several news agencies, the president of the DePuy unit, which is part of Johnson & Johnson, has reportedly claimed that all 93,000 units of ASR all-metal hip implants linked to the 2010 recall were pulled from the market for not meeting clinical expectations.

The multiple articles covering this story noted that the recall was not linked in any way with design defects, which was what ultimately was linked to several cases of adverse reactions that led to the over 10,000 lawsuits filed against Johnson & Johnson, the health-care product giant.

During the trial of the second lawsuit filed against the company over defective all-metal hip implants, attorneys reported that the Plaintiff, a 54-year-old woman from Illinois, had to unfortunately have her hip implant replaced three years after having it first implanted in 2008. According to the reports, the defect linked to the implant’s design may have caused the hip implant to shed cobalt and chromium debris into the woman’s tissues and bloodstream over time, increasing the risk of certain health problems. The first case was tried in Los Angeles recently and the jury found that J&J was at fault for producing a defective ASR hip implant. The jury hearing the L.A. case later awarded the victim with $8.3 million as a result.

The company still faces 10,750 lawsuits over the defective hip implants. According to the article, a document that was presented during trial shows that the company’s Health Hazard/Risk Evaluation Review Board had three possible explanation related to the hip implant recall that had been prepared for publishing. The list of possible reasons included a potential design defect. According to the document, the possible defect could affect the implant’s performance and cause it to pose a health issues to users.

Attorneys for J&J and the DePuy unit that oversees the design and production of the affected hip implants have claimed that many factors were linked to the overall high revision rate of the hip implants. According to the official documents, about 13 percent of all ASR hip implants failed within five years in the UK, which sparked concerns related to the possible defects linked to the product’s design.

Johnson & Johnson is the world’s largest seller of health-care products. Since the revision rate linked to ASR hip implants was higher than expected, according to the company, which led to the major recall that affected thousands of patients in the country.

To learn more about the second trial, follow this link to read the full article.

Comments are closed.